Header Logo

Connection

Anil Chandraker to Time Factors

This is a "connection" page, showing publications Anil Chandraker has written about Time Factors.
Connection Strength

0.495
  1. Batal I, Mohan S, De Serres SA, Vasilescu ER, Tsapepas D, Crew RJ, Patel SS, Serban G, McCune K, Husain SA, Chang JH, Herter JM, Bhagat G, Markowitz GS, D'Agati VD, Hardy MA, Ratner L, Chandraker A. Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes. Kidney Int. 2018 05; 93(5):1227-1239.
    View in: PubMed
    Score: 0.086
  2. Riella LV, Safa K, Yagan J, Lee B, Azzi J, Najafian N, Abdi R, Milford E, Mah H, Gabardi S, Malek S, Tullius SG, Magee C, Chandraker A. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation. 2014 Jun 27; 97(12):1247-52.
    View in: PubMed
    Score: 0.067
  3. Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, Mandelbrot DA, Adey DB, Heher E, Fan PY, Conte S, Dyer-Ward C, Chandraker A. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014 Mar; 9(3):583-9.
    View in: PubMed
    Score: 0.065
  4. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1298-304.
    View in: PubMed
    Score: 0.050
  5. Chandraker A, Huurman V, Hallett K, Yuan X, Tector AJ, Park CH, Lu E, Zavazava N, Oaks M. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation. 2005 Apr 27; 79(8):897-903.
    View in: PubMed
    Score: 0.035
  6. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy. 2004 Oct; 24(10):1323-30.
    View in: PubMed
    Score: 0.034
  7. Palsson R, Chandraker AK, Curhan GC, Rennke HG, McMahon GM, Waikar SS. The association of calcium oxalate deposition in kidney allografts with graft and patient survival. Nephrol Dial Transplant. 2020 05 01; 35(5):888-894.
    View in: PubMed
    Score: 0.025
  8. Zazueta OE, Preston SE, Moniodis A, Fried S, Kim M, Townsend K, Wood I, Boukedes S, Guleria I, Camp P, El-Chemaly S, Rosas IO, Chandraker A, Milford E, Goldberg HJ. The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation. 2017 09; 101(9):2207-2212.
    View in: PubMed
    Score: 0.021
  9. Safa K, Ohori S, Borges TJ, Uehara M, Batal I, Shimizu T, Magee CN, Belizaire R, Abdi R, Wu C, Chandraker A, Riella LV. Salt Accelerates Allograft Rejection through Serum- and Glucocorticoid-Regulated Kinase-1-Dependent Inhibition of Regulatory T Cells. J Am Soc Nephrol. 2015 Oct; 26(10):2341-7.
    View in: PubMed
    Score: 0.018
  10. De Serres SA, Mfarrej BG, Grafals M, Riella LV, Magee CN, Yeung MY, Dyer C, Ahmad U, Chandraker A, Najafian N. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1018-25.
    View in: PubMed
    Score: 0.014
  11. Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients. Ann Pharmacother. 2011 Sep; 45(9):e48.
    View in: PubMed
    Score: 0.014
  12. Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Pharmacotherapy. 2011 Jun; 31(6):566-73.
    View in: PubMed
    Score: 0.013
  13. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther. 2007; 12(1):1-6.
    View in: PubMed
    Score: 0.010
  14. Winkelmayer WC, Chandraker A, Alan Brookhart M, Kramar R, Sunder-Plassmann G. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006 Dec; 21(12):3559-66.
    View in: PubMed
    Score: 0.010
  15. Kim KS, Denton MD, Chandraker A, Knoflach A, Milord R, Waaga AM, Turka LA, Russell ME, Peach R, Sayegh MH. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol. 2001 Mar; 158(3):977-86.
    View in: PubMed
    Score: 0.007
  16. Mackinnon FG, Ho Y, Blake MS, Michon F, Chandraker A, Sayegh MH, Wetzler LM. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. J Infect Dis. 1999 Sep; 180(3):755-61.
    View in: PubMed
    Score: 0.006
  17. Kato H, Onodera K, Chandraker A, Volk HD, Sayegh MH, Kupiec-Weglinski JW. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. Transplant Proc. 1998 Jun; 30(4):1063-4.
    View in: PubMed
    Score: 0.005
  18. Schaub M, Stadlbauer TH, Chandraker A, Vella JP, Turka LA, Sayegh MH. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol. 1998 May; 9(5):891-8.
    View in: PubMed
    Score: 0.005
  19. Nadeau K, Azuma H, Chandraker A, Sayegh MH, Tilney NL. Inhibition of CD28-B7 T-cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):1038.
    View in: PubMed
    Score: 0.005
  20. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.